Robert Bélanger

1.2k total citations
42 papers, 906 citations indexed

About

Robert Bélanger is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Robert Bélanger has authored 42 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 16 papers in Immunology and 9 papers in Genetics. Recurrent topics in Robert Bélanger's work include Hematopoietic Stem Cell Transplantation (22 papers), T-cell and B-cell Immunology (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Robert Bélanger is often cited by papers focused on Hematopoietic Stem Cell Transplantation (22 papers), T-cell and B-cell Immunology (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Robert Bélanger collaborates with scholars based in Canada, United States and France. Robert Bélanger's co-authors include Claude Perreault, M Gyger, Denis‐Claude Roy, Y Bonny, Sylvie Brochu, Francine Décary, Lambert Busque, Jean Roy, M Girard and Georges‐Étienne Rivard and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Bone and Joint Surgery.

In The Last Decade

Robert Bélanger

42 papers receiving 869 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Bélanger Canada 16 551 308 189 164 128 42 906
R. Or Israel 16 698 1.3× 410 1.3× 128 0.7× 267 1.6× 101 0.8× 48 1.0k
Daniel Stachel Germany 15 487 0.9× 372 1.2× 239 1.3× 226 1.4× 123 1.0× 45 1.1k
J. A. Gastaut France 18 336 0.6× 271 0.9× 202 1.1× 232 1.4× 127 1.0× 40 937
E.D. Agura United States 13 753 1.4× 307 1.0× 90 0.5× 200 1.2× 172 1.3× 17 981
A. Grigg Australia 18 377 0.7× 144 0.5× 154 0.8× 272 1.7× 179 1.4× 37 825
Mats Remberger Sweden 18 583 1.1× 247 0.8× 185 1.0× 398 2.4× 145 1.1× 37 1.1k
Carmen Martín Spain 19 646 1.2× 252 0.8× 153 0.8× 246 1.5× 133 1.0× 47 916
Y Morishita Japan 15 511 0.9× 374 1.2× 105 0.6× 188 1.1× 88 0.7× 34 869
G. B. Vogelsang United States 17 963 1.7× 405 1.3× 101 0.5× 267 1.6× 186 1.5× 28 1.2k
Manuel Abecasis Portugal 11 488 0.9× 198 0.6× 230 1.2× 220 1.3× 86 0.7× 24 865

Countries citing papers authored by Robert Bélanger

Since Specialization
Citations

This map shows the geographic impact of Robert Bélanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Bélanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Bélanger more than expected).

Fields of papers citing papers by Robert Bélanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Bélanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Bélanger. The network helps show where Robert Bélanger may publish in the future.

Co-authorship network of co-authors of Robert Bélanger

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Bélanger. A scholar is included among the top collaborators of Robert Bélanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Bélanger. Robert Bélanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vose, Julie M., Amit Panwalkar, Robert Bélanger, et al.. (2007). A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. Leukemia & lymphoma. 48(1). 39–45. 6 indexed citations
2.
Laneuville, Pierre, Michael J. Barnett, Robert Bélanger, et al.. (2006). Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia. Current Oncology. 13(6). 201–221. 10 indexed citations
3.
Gilbert, Clare, Jean Roy, Robert Bélanger, et al.. (2001). Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients. Antimicrobial Agents and Chemotherapy. 45(12). 3669–3671. 28 indexed citations
4.
Tyring, Stephen K., Robert Bélanger, W. R. Bezwoda, et al.. (2001). A Randomized, Double-Blind Trial of Famciclovir Versus Acyclovir for the Treatment of Localized Dermatomal Herpes Zoster in Immunocompromised Patients. Cancer Investigation. 19(1). 13–22. 53 indexed citations
5.
Blanc, Richard Le, Robert Bélanger, Lambert Busque, et al.. (2001). Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplantation. 28(9). 841–848. 51 indexed citations
6.
Lazarus, Hillard M., et al.. (1999). Intravenous Penciclovir for Treatment of Herpes Simplex Infections in Immunocompromised Patients: Results of a Multicenter, Acyclovir-Controlled Trial. Antimicrobial Agents and Chemotherapy. 43(5). 1192–1197. 25 indexed citations
7.
8.
Bélanger, Robert, et al.. (1996). Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.. PubMed. 17(3). 315–22. 1 indexed citations
9.
Pichert, Gabriella, Denis‐Claude Roy, R Gonin, et al.. (1995). Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.. Journal of Clinical Oncology. 13(7). 1704–1713. 33 indexed citations
10.
Hébert, Marie-Josèe, François Madore, Robert Bélanger, et al.. (1994). Mesangiolysis Associated With Bone Marrow Transplantation: New Insights on Possible Etiogenic Factors. American Journal of Kidney Diseases. 23(6). 882–883. 7 indexed citations
11.
12.
Bélanger, Robert, Claude Perreault, Y Bonny, et al.. (1993). Allogeneic bone marrow transplantation following busulfan‐cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. British Journal of Haematology. 85(4). 706–713. 12 indexed citations
13.
14.
Gyger, M, Giovanni D’Angelo, Robert Bélanger, et al.. (1992). Cytogenetic characterization of primary refractory anemia. American Journal of Hematology. 41(4). 241–248. 7 indexed citations
15.
Perreault, Claude, Annika Allard, Sylvie Brochu, et al.. (1990). Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.. PubMed. 6(2). 127–35. 9 indexed citations
16.
Perreault, Claude, Francine Décary, Sylvie Brochu, et al.. (1990). Minor histocompatibility antigens. Blood. 76(7). 1269–1280. 128 indexed citations
17.
Perreault, Claude, M Gyger, Giovanni D’Angelo, et al.. (1989). Chronic B‐cell lymphocytosis. European Journal Of Haematology. 42(4). 361–367. 23 indexed citations
18.
Bélanger, Robert, M Gyger, Claude Perreault, Y Bonny, & Jean St‐Louis. (1988). Bone marrow transplantation for myelodysplastic syndromes. British Journal of Haematology. 69(1). 29–33. 34 indexed citations
19.
Perreault, Claude, et al.. (1985). Serum immunoglobulin levels following allogeneic bone marrow transplantation. Annals of Hematology. 51(3). 137–142. 15 indexed citations
20.
Perreault, Claude, Robert Bélanger, Y Bonny, et al.. (1985). Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft‐versus‐host disease. British Journal of Haematology. 60(2). 253–260. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Or Breakdown of academic impact, for papers by Daniel Stachel Breakdown of academic impact, for papers by J. A. Gastaut Breakdown of academic impact, for papers by E.D. Agura Breakdown of academic impact, for papers by A. Grigg Breakdown of academic impact, for papers by Mats Remberger Breakdown of academic impact, for papers by Carmen Martín Breakdown of academic impact, for papers by Y Morishita Breakdown of academic impact, for papers by G. B. Vogelsang Breakdown of academic impact, for papers by Manuel Abecasis
Rankless by CCL
2026